ArticlePoultry science2026
Lactococcus lactis NZ3900/pNZ8149-ChIL-4-ChIL-2 alleviates compound stress in chicks via reshaping immune homeostasis, gut microbiota and intestinal health.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The poultry industry faces significant challenges due to multiple concurrent stressors, such as heat stress (HS) and live Eimeria vaccination. This study aimed to evaluate the efficacy of Lactococcus lactis NZ3900/pNZ8149-ChIL-4-ChIL-2 (RLIL4/2) as a trained immunity inducer in mitigating the adverse effects of combined stressors in young chicks, with a focus on systemic immune balance, growth performance, and intestinal health. Four-day-old ISA White pullets were randomly allocated into 4 groups with 3 biological replicates (20 birds/replicate): the C group (mild HS, 72≤THI≤79, 12h/day, basic crude protein diet [CP ≥23%], no Eimeria vaccine, no RLIL4/2), the A group (moderate HS [MHS], low crude protein diet [CP ≤17%], Eimeria vaccine), the R group (MHS, CP 17% diet with oral RLIL4/2), and the T group (same as group A plus oral RLIL4/2 1 h pre-vaccination). Compared with the control group, compound stress suppressed chick growth and immune‑organ development, triggering immune response imbalance, gut microbiota dysbiosis, intestinal barrier injury, and a marked expansion of pathogenic bacteria. RLIL4/2 could mitigate these pathological alterations and preserve host health, immune function, and microbiota homeostasis. Moreover, RLIL4/2 is capable of inducing trained immunity in macrophages, thereby enabling a more rapid immune response upon challenge. These results showed that RLIL4/2 relieves compound stresse-induced gosling enteritis by maintaining cytokine, tight junctions, and immunoglobulin relatively stable and improving the disorder of intestinal flora. RLIL4/2, an compound regulator, boosts disease preventive efficacy in chicks subjected to compound stress through multiple molecular pathways, and its application provides a novel intervention approach for avian disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.